What is this summary about? This is a summary of a research study (known as a clinical trial)
called the LIBERTY extension study. The LIBERTY extension study is a long-term study …

Objective To evaluate the impact of elagolix, an oral gonadotropin-releasing hormone
antagonist, on the health-related quality of life (HRQL) in women with heavy menstrual …

Objective In the 24-week, phase 3 LIBERTY 1 (L1) and LIBERTY 2 (L2) trials, relugolix
combination therapy (relugolix-CT (relugolix 40 mg, estradiol 1 mg, norethisterone acetate …

Background Uterine fibroids are a common cause of heavy menstrual bleeding and pain.
Treatment with the combination of relugolix (an oral gonadotropin-releasing hormone …

Objective To evaluate the efficacy and safety of 24 weeks of treatment with the oral GnRH
receptor antagonist, relugolix, in combination with estradiol (E2) and norethindrone acetate …

Objective Relugolix 40 mg is a non-peptide gonadotropin-releasing hormone receptor
antagonist being developed for use in combination with estradiol 1 mg and norethindrone …

Objective In the LIBERTY 1 and 2 trials, once-daily relugolix combination therapy (Rel-CT)
reduced menstrual blood loss (MBL) volume and pain in women with uterine fibroids (UF) …

METHODS: This randomized, double-blind, placebo-controlled, phase 2 study was
designed to evaluate relugolix 10 mg, 20 mg and 40 mg administered orally once daily for …

Treatment of uterine fibroids (UF) and endometriosis (EM) has relied on the surgical skills of
gynecologists to improve symptoms and potentially alter the course of these debilitating …

ABSTRACT Introduction Uterine Fibroids (UFs) are the most predominant benign tumor in
women who are coming of reproductive age, and causes intense economic load priced in …